Pfizer Inc

PFE-N

NYSE:PFE

34.20
0.19 (0.55%)
Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. Pfizer is considered one of the world's largest pharmaceutical companies.
More at Wikipedia

Analysis and Opinions about PFE-N

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
February 19, 2021
Their vaccine will give them a boost in the near term, but it is not sustainable for their long term growth outlook. Their product pipeline is really hampering their growth outlook. Needs more visibility in their pipeline. It will continue to be depressed until there is movement here.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 19, 2021
Their vaccine will give them a boost in the near term, but it is not sustainable for their long term growth outlook. Their product pipeline is really hampering their growth outlook. Needs more visibility in their pipeline. It will continue to be depressed until there is movement here.
HOLD
HOLD
February 17, 2021
He is focused on US healthcare sector, though he's not looking at the vaccine angle. You'll do fine long term. Reasonably valued, development potential. There will be an overhang as some of the fast money comes out and goes to pharma companies left in the dust.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 17, 2021
He is focused on US healthcare sector, though he's not looking at the vaccine angle. You'll do fine long term. Reasonably valued, development potential. There will be an overhang as some of the fast money comes out and goes to pharma companies left in the dust.
PAST TOP PICK
PAST TOP PICK
February 11, 2021
(A Top Pick Jan 17/20, Down 15%) Committed to transitioning to a more pure play R&D-focused biopharmaceutical company. But it hasn't delivered. Consumer businesses are being spun out. Great vaccine business, but there's competition. OK at current valuations. Risk profile has changed. Finances will be impacted by number of vaccines actually needed.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 11, 2021
(A Top Pick Jan 17/20, Down 15%) Committed to transitioning to a more pure play R&D-focused biopharmaceutical company. But it hasn't delivered. Consumer businesses are being spun out. Great vaccine business, but there's competition. OK at current valuations. Risk profile has changed. Finances will be impacted by number of vaccines actually needed.
PAST TOP PICK
PAST TOP PICK
February 8, 2021
(A Top Pick Feb 11/20, Up 1%) You are looking for their dividend but a lot of it sold off during 2020 and he eventually sold off in November on the vaccine news. He moved to another vaccine company.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 8, 2021
(A Top Pick Feb 11/20, Up 1%) You are looking for their dividend but a lot of it sold off during 2020 and he eventually sold off in November on the vaccine news. He moved to another vaccine company.
WEAK BUY
WEAK BUY
February 1, 2021

He likes it. It is a way to play the vaccines. He has had MRNA-Q in the portfolio for a while. The growth of vaccines will be with us for some time. He feels the growth is there. He prefers to play the group through an ETF like XBI-T. You are going to see more money spent in vaccinations and they will be with us for a long, long time.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 1, 2021

He likes it. It is a way to play the vaccines. He has had MRNA-Q in the portfolio for a while. The growth of vaccines will be with us for some time. He feels the growth is there. He prefers to play the group through an ETF like XBI-T. You are going to see more money spent in vaccinations and they will be with us for a long, long time.

DON'T BUY
DON'T BUY
January 19, 2021

They're not in warp speed now, given the problems in vaccine distribution in various states. Pfizer's problem is that it isn't innovative like Eli Lilly or Bristol-Myers.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 19, 2021

They're not in warp speed now, given the problems in vaccine distribution in various states. Pfizer's problem is that it isn't innovative like Eli Lilly or Bristol-Myers.

DON'T BUY
DON'T BUY
January 14, 2021

An area that's started to act better recently. Well managed. But doesn't understand what the catalysts are. Doesn't find it compelling. Consider the picks and shovels instead, like Agilent or Danaher, who benefit from growth in everyone's pipeline.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 14, 2021

An area that's started to act better recently. Well managed. But doesn't understand what the catalysts are. Doesn't find it compelling. Consider the picks and shovels instead, like Agilent or Danaher, who benefit from growth in everyone's pipeline.

DON'T BUY
DON'T BUY
January 11, 2021
It has an interesting problem. It has the solution to COVID-19 and they have orders for billions of doses but the stock has not done anything. The earnings forecast for the company are going sideways. Analysts probably think the demand for COVID vaccines will decline sharply when COVID is over and then there will be all these plants that are idle. So looking longer term, they see the earnings as flat.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 11, 2021
It has an interesting problem. It has the solution to COVID-19 and they have orders for billions of doses but the stock has not done anything. The earnings forecast for the company are going sideways. Analysts probably think the demand for COVID vaccines will decline sharply when COVID is over and then there will be all these plants that are idle. So looking longer term, they see the earnings as flat.
DON'T BUY
DON'T BUY
December 29, 2020

A core name, but it's hard for big pharma names like this to find a product to drive growth. He prefers biotechs which offer better growth, even ETFs like IBB.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
December 29, 2020

A core name, but it's hard for big pharma names like this to find a product to drive growth. He prefers biotechs which offer better growth, even ETFs like IBB.

COMMENT
COMMENT
December 14, 2020

PFE-N vs. MRNA-Q. PFE-N is a much, much larger company. MRNA-Q is bringing their first product ever to market. PFE-N is well established and their vaccine is one of many products. They also have many drugs going off patent but their pipeline is looking better. PFE-N is not one of her core holdings but their earnings growth should improve over time.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
December 14, 2020

PFE-N vs. MRNA-Q. PFE-N is a much, much larger company. MRNA-Q is bringing their first product ever to market. PFE-N is well established and their vaccine is one of many products. They also have many drugs going off patent but their pipeline is looking better. PFE-N is not one of her core holdings but their earnings growth should improve over time.

PAST TOP PICK
PAST TOP PICK
December 8, 2020
(A Top Pick Sep 24/20, Up 17.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE has achieved its $42 target. To be disciplined, we are recommending covering 50% of the position. We are also recommending to trail up the stop to $33.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
December 8, 2020
(A Top Pick Sep 24/20, Up 17.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE has achieved its $42 target. To be disciplined, we are recommending covering 50% of the position. We are also recommending to trail up the stop to $33.
SELL
SELL
November 23, 2020
He sold it about two weeks ago when they put out the vaccine news. He was looking to trim or sell anyway. They are going through the spin-off of their generic business (UpJohn). He does not think the vaccine will be a long term driver on their financials. They had a miss in their oncology program back in June that impacted the long term growth rate going forward.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
November 23, 2020
He sold it about two weeks ago when they put out the vaccine news. He was looking to trim or sell anyway. They are going through the spin-off of their generic business (UpJohn). He does not think the vaccine will be a long term driver on their financials. They had a miss in their oncology program back in June that impacted the long term growth rate going forward.
DON'T BUY
DON'T BUY
November 19, 2020
The positive vaccine news helped the stock rally but it has since given up the gains. There is not as much growth as you would like, and pay 13x earnings. Likes other names that has better growth. It has been moving sideways. The only reason to own it is for the dividend.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
November 19, 2020
The positive vaccine news helped the stock rally but it has since given up the gains. There is not as much growth as you would like, and pay 13x earnings. Likes other names that has better growth. It has been moving sideways. The only reason to own it is for the dividend.
BUY
BUY
October 27, 2020
Allan Tong’s Discover Picks The divvy pays nearly 4%. Investors are already pushing up the Pfizer stock near 52-week highs and price target, both $41, though it trades at a PE of only 14.9x. Currently, one analyst rates Pfizer stock a strong buy, 11 more a buy, nine a hold, and one a sell, its strongest recommendations so far this year. It's a strong company, but upside may be limited. Read 3 Promising Diversified Coronavirus Vaccine Stocks Ahead of the Game: Fall Update for our full analysis.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
October 27, 2020
Allan Tong’s Discover Picks The divvy pays nearly 4%. Investors are already pushing up the Pfizer stock near 52-week highs and price target, both $41, though it trades at a PE of only 14.9x. Currently, one analyst rates Pfizer stock a strong buy, 11 more a buy, nine a hold, and one a sell, its strongest recommendations so far this year. It's a strong company, but upside may be limited. Read 3 Promising Diversified Coronavirus Vaccine Stocks Ahead of the Game: Fall Update for our full analysis.
COMMENT
COMMENT
October 20, 2020
Tough to analyze now. He's awaiting their drug test results. They're in the middle of spinning off long-life assets, including Viagra (later this year or next). This spinning-off will transform Pfizer from boring long-life assets to focus on R&D drugs. He expects their Covid vaccine to succeed the first. The CEO issued an update Friday and the testing data so far looks promising. There haven't been any adverse test results yet. He expects data in 2-5 weeks. He's closely watching this. Their Covid vaccine will be a catalyst short-term.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
October 20, 2020
Tough to analyze now. He's awaiting their drug test results. They're in the middle of spinning off long-life assets, including Viagra (later this year or next). This spinning-off will transform Pfizer from boring long-life assets to focus on R&D drugs. He expects their Covid vaccine to succeed the first. The CEO issued an update Friday and the testing data so far looks promising. There haven't been any adverse test results yet. He expects data in 2-5 weeks. He's closely watching this. Their Covid vaccine will be a catalyst short-term.
Showing 1 to 15 of 702 entries

Pfizer Inc(PFE-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 8

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 13

Total Signals / Votes : 22

Stockchase rating for Pfizer Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Pfizer Inc(PFE-N) Frequently Asked Questions

What is Pfizer Inc stock symbol?

Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N

Is Pfizer Inc a buy or a sell?

In the last year, 22 stock analysts published opinions about PFE-N. 8 analysts recommended to BUY the stock. 13 analysts recommended to SELL the stock. The latest stock analyst recommendation is DON'T BUY. Read the latest stock experts' ratings for Pfizer Inc.

Is Pfizer Inc a good investment or a top pick?

Pfizer Inc was recommended as a Top Pick by Christine Poole on 2021-02-19. Read the latest stock experts ratings for Pfizer Inc.

Why is Pfizer Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Pfizer Inc worth watching?

22 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.

What is Pfizer Inc stock price?

On 2021-03-04, Pfizer Inc (PFE-N) stock closed at a price of $34.2.